Register for our free email digests:
Division of Pfizer Inc.
Latest From Bukwang Pharmaceutical Co. Ltd.
MLR-1023, a repositioned oral compound being developed for type 2 diabetes by Melior and Bukwang, is set to move into Phase IIb in the US and South Korea, and the firms are looking to its novel mechanism of action, improved tolerability and efficacy to carve a niche in a highly competitive sector.
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
South Korean companies that withdrew IPO plans late last year due largely to the crowded year-end offering market are now returning. Among them are drug developers Anterogen and Qurient, which successfully relaunched floats in the second-tier Kosdaq market in February.
A new regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
David T Hung, MD, Pres. & CEO
Jennifer Jarrett, CFO
Joseph Lobacki, Chief Commercial Officer
Marion McCourt, COO
- Contact Info
Phone: (415) 543-3470
525 Market St.
San Francisco, CA 94105
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.